Agrylin Drug Use-Result Survey

NCT03625895 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1826

Last updated 2023-02-27

Study results available
· View outcomes & findings →

Summary

The objective of this survey is to collect data to evaluate the safety and efficacy of anagrelide hydrochloride in the post-marketing phase in participants diagnosed with Essential Thrombocythemia (ET).

Conditions

  • Essential Thrombocythemia (ET)

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-25
Primary Completion
2021-03-11
Completion
2021-03-11

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03625895 on ClinicalTrials.gov